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Background: To determine the recommended dose and evaluate the
response rate and toxicity of triplet chemotherapy using cisplatin,
docetaxel, and irinotecan for non-small cell lung cancer (NSCLC)
patients with stage IIIB or IV.
Methods: A total of 65 patients (33 men and 32 women) with
advanced NSCLC, a good performance status, and 65 years of age
or younger were included in these phase I/II studies. The median age
was 52 years. Most patients had performance status 1 (49/65) and
stage IV disease (49/65). Adenocarcinoma was the most common
tumor histology (55 patients). Cisplatin and docetaxel were given on
day 1 and irinotecan on day 2; the cycles were repeated every 3
weeks.
Results: In the phase I study, the maximum tolerated doses of
combination cisplatin/docetaxel/irinotecan were, respectively, 80/
60/60 (mg/m2) and the recommended doses for the phase II study
were determined to be 60/60/60 (mg/m2), respectively. The dose-
limiting toxicities were neutropenia, neutropenic fever, and diarrhea.
In the phase II study, 157 cycles of chemotherapy were delivered to
49 patients (median three cycles per patient). The objective response
rate was 57.1% (95% confidence interval: 43.1%–71.1%). The
median survival time and the actual 2-, 3- and estimated 5-year
survival rates were 17 months, 33%, 25%, and 18%, respectively.
Grade 3/4 toxicities consisted of neutropenia (92%), neutropenic
fever (45%), nausea/vomiting (27%), diarrhea (35%), and hepatic
toxicity (2%); there were no cases of treatment-related death.
Conclusion: This triplet chemotherapy has shown a promising
activity against advanced NSCLC according to admission-based
treatment with adequate supportive care. The principal toxicity was
neutropenic fever, but supportive care should be explored to reduce
this incidence.
(J Thorac Oncol. 2007;2: 44–50)
Lung cancer remains a leading cause of cancer death indeveloped countries, and approximately 80% of lung can-
cer is detected at an advanced stage. At the time of diagnosis,
approximately half of all patients with non-small cell lung
cancer (NSCLC) have distant disease.1 For these patients,
survival beyond 5 years is uncommon.2 For the past 10
years, new agents have been successively introduced to the
clinical care of advanced NSCLC. Platinum-based doublet
chemotherapy including a new agent remains the standard
treatment regimen for advanced NSCLC patients with a
good performance status (PS)3; however, the efficacy of
platinum-based doublet chemotherapy appears to have reached
a plateau.4,5
A recent meta-analysis has shown that adding a third
drug to a doublet regimen significantly improved the objec-
tive response rate, but not the overall survival, and that grade
3/4 toxicities occurred more frequently in triplet regimens
than in doublet regimens.6 This meta-analysis, however, did
not consider the kind of anticancer agents nor the treatment
schedule. Accordingly, the conclusions of this meta-analysis
cannot be universally applied to each experimental trial.
Using a multivariate analysis, we demonstrated both a sur-
vival advantage and a better response rate by adding ifosf-
amide to the doublet chemotherapy.7 Recently, Paccagnella et
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al.8 clearly showed that adding gemcitabine to doublet che-
motherapy improved the overall survival.
In this study, we wanted to establish the response rate
of a new triplet therapy. The dose schedule and choice of
drug regimen in this study was cisplatin and docetaxel on day
1 and irinotecan on day 2 according to the following concept.
First, cisplatin showed a significant tumor reduction and a
favorable survival advantage compared to carboplatin, even
in advanced NSCLC.9 A meta-analysis confirmed the supe-
riority of cisplatin over carboplatin when combined with a
new drug.10 We therefore selected cisplatin to maximize the
tumor response. Second, doublet chemotherapy of cisplatin
and docetaxel had shown good response rates in a phase II
trial when we designed this trial,11 and it also demonstrated a
significant survival advantage in later phase III trials.12,13 In
addition, this combination did not show antagonism in an ex
vivo experiment we performed.14 We therefore selected a
combination of cisplatin and docetaxel as the core chemo-
therapy to add the third drug. Third, the drug sensitivity panel
consisting of 24 lung cancer cell lines that we have previously
reported showed a correlation coefficient of 50% inhibition
concentrations of docetaxel and an active metabolite of iri-
notecan (r  0.115).15 This is the lowest finding compared to
the correlation coefficients of docetaxel versus gemcitabine
(r  0.519), docetaxel versus paclitaxel (r  0.459), and
docetaxel versus vinorelbine (r  0.388).15 Docetaxel in
addition to irinotecan among the new three drugs showed the
broadest antitumor spectrum, but a simultaneous combination
of docetaxel and irinotecan showed a substantial antagonistic
effect in one of the three cell lines tested.14 Therefore, the
administration of docetaxel and irinotecan was split, although
a synergistic effect between cisplatin and irinotecan has been
reported.16 Because a strong synergism between these two
drugs for tumor cells in an ex vivo experiment sometimes
produced more severe toxicity in a clinical setting, we gave
priority to the antitumor spectrum in this trial.
PATIENTS AND METHODS
Eligibility Criteria
The eligibility criteria for the phase I/II study were as
follows: a histologically or cytologically proven diagnosis of
NSCLC, no previous treatment for NSCLC, age 65 years or
younger (we selected the younger population for very inten-
sive chemotherapy), stage IIIB disease not suitable for tho-
racic radiotherapy and stage IV disease, PS of 0 or 1, the
presence of measurable disease, adequate organ function
(white blood cell count 4000 to 12,000/l, platelet count
100,000/l, serum creatinine 1.5 mg/dl, 24-hour creati-
nine clearance60 ml/min at least twice, total bilirubin1.5
mg/dl, alanine transaminase and asparagine transaminase
twofold or less of the upper limit of normal, arterial oxygen
partial pressure 60 Torr or arterial oxygen saturation
90%), and no other malignancy during the previous 5 years.
Any patients with symptomatic brain metastasis or serious
underlying diseases, such as interstitial pneumonia, serious
cardiac disease, uncontrolled diabetes mellitus, serious infec-
tions, and massive pleural or pericardial effusion, were ex-
cluded. The protocol was approved by the institutional review
board and written informed consent was obtained from all
subjects.
Phase I/II Study
The primary endpoint of the phase I study was carried
out to determine the maximum tolerated doses (MTDs),
dose-limiting toxicity (DLT), and the recommended doses of
the drugs for the subsequent phase II study. The primary
endpoint of the phase II study was the response rate and
principal toxicities.
Evaluation
For patients in both studies, tumors were staged based
on the following: physical examination, chest radiograph,
bone scintigraphy, computed tomography of the chest and
abdomen, magnetic resonance imaging of the brain, and
fiberoptic bronchoscopy. The staging assessment was per-
formed according to the Union International Contre le Cancer
TNM classification for lung cancer staging.17 Before the first
cycle of treatment, a complete blood cell count, blood chem-
istry tests, and a urinalysis were all performed. These exam-
inations together with chest radiography were repeated at
least once per week after the initial evaluation, whereas other
investigations were repeated every 3 to 4 weeks to evaluate
the target lesions. A complete blood count was routinely
performed twice weekly from the beginning of chemother-
apy. In addition, a complete blood count was repeated daily
until recovery, when the absolute neutrophil count decreased
to 500/l or the leukocyte count was 1000/l. The tumor
response was assessed by extramural reviewers using World
Health Organization criteria.17 Toxicity was assessed using
the National Cancer Institute Common Toxicity Criteria ver-
sion 2.0/Revised.
Dose escalation for the phase I portion
The doses were escalated in each successive cohort of
at least three new patients according to the dose escalation
scheme in Table 1. The doses were escalated based on the
toxicity encountered during the first cycle of chemotherapy,
and the doses were not escalated for individual patients. DLT
was defined as grade 4 hematologic toxicity lasting 4 days,
any grade 3/4 nonhematologic toxicity that met National
Cancer Institute Common Toxicity Criteria except for nausea,
vomiting, and grade 3 febrile neutropenia lasting 4 days.
If DLT occurred in one or two of the three initial
patients at a particular dose level, then three additional
patients were treated at the same dose level to define the
TABLE 1. Dose Escalation in the Phase I Study
Level
Cisplatin
(mg/m2)
Docetaxel
(mg/m2)
Irinotecan
(mg/m2)
Patients
Entered With DLT
1 60 60 40 6 1
2 60 60 50 6 2
3 60 60 60 6 2
4 80 60 60 3 3
DLT, dose-limiting toxicity.
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frequency of that toxicity. If all three patients or at least three
of six patients experienced DLT, then enrollment at this dose
level was ceased, the dose level was determined as the MTDs,
and the preceding dose level was designated as the recom-
mended doses for the phase II study.
Supportive care
In the case of grade 3/4 leukopenia or neutropenia, the
patients received recombinant human granulocyte colony–
stimulating factor (rhG-CSF) subcutaneously and levofloxa-
cin orally. Patients who experienced grade 4 neutropenia or
grade 3/4 febrile neutropenia in the first cycle received
prophylactic rhG-CSF in the subsequent cycles. In this trial,
we could not employ rhG-CSF until the emergence of grade
4 neutropenia or neutropenic fever because the medical in-
surance system does not cover prophylactic rhG-CSF at the
first cycle of chemotherapy in Japan. If loose stools or
diarrhea occurred, then the patient was treated with loperam-
ide. Antiemetic prophylaxis consisted of 8 mg dexametha-
sone and 6 mg granisetron on day 1, and 3 mg granisetoron
on days 2 and 3.
When the patients recovered to grade 0 or 1 leukocy-
topenia/neutropenia without rhG-CSF support, no diarrhea
without loperamide for at least 3 days, and grade 0 or
baseline, then the triplet chemotherapy was repeated within 4
weeks.
Dose modification
Dose reductions or omissions were permitted based on
toxicity. The cisplatin dose was reduced to 30 mg/m2 if the
creatinine clearance level was 30 to 60 ml/min. Cisplatin was
discontinued when the creatinine clearance level was less
than 30 ml/min. If the patients experienced DLTs other than
renal impairment, then the subsequent dose of irinotecan was
reduced by 10 mg/m2.
Drug administration
On day 1, docetaxel was given as a 1-hour infusion, and
then subsequently cisplatin was administered as a 1-hour
infusion. The patients were hydrated with 2 liters of mainte-
nance solution. On day 2, irinotecan was also given as a
1-hour infusion. Patients were hydrated with 2 liters of
maintenance solution. On day 3, the patients were hydrated
with 1 liter of maintenance solution.
Statistical Considerations
The sample size of 43 patients for the phase II study
was calculated based on the assumption that 50% of the
patients would respond, with a 95% confidence interval (CI)
15%. Assuming that 15% of patients would not be assess-
able for response, the accrual goal was 50 patients including
those who received chemotherapy at the recommended dose
level in the phase I study. If five patients or more did not
achieve a partial response (PR) when 25 patients were ac-
crued in an interim analysis, this trial was discontinued
because the response rate was assumed to be 20%.
The survival time was defined as the period from the
beginning of treatment to death or the last follow-up evalu-
ation, and the time to progression was defined as the period
from the beginning of the treatment to date of progressive
disease (PD) or death. The survival curves were calculated
using the Kaplan-Meier method. The log-rank test was em-
ployed to detect the differences in survival.
RESULTS
Patient Characteristics
Between May 1998 and March 2002, 65 patients were
enrolled at Okayama University Hospital and five affiliated
hospitals in Japan. The characteristics of the 65 patients are
listed in Table 2. In the phase I study, 21 patients were treated
at one of the four dose levels (Table 1). For the phase II study,
50 patients, including six patients in the phase I study who
were treated with the recommended doses, were enrolled
(Table 1). Overall, 27 men and 23 women with a median age
of 52 years (range, 35–65 years) were included. Forty pa-
tients (80%) had adenocarcinoma, six (12%) squamous cell
carcinoma, three (6%) large cell carcinoma, and one (2%)
unclassified carcinoma. Eleven patients (22%) had stage IIIB
and 39 (78%) had stage IV disease. Ten patients (20%) had
5% weight loss within 6 months. The number of metastatic
sites and site of metastatic organs in the phase II study are
shown in Table 3. In addition, 27 of the patients (69%)
showed one metastatic site. The most common metastatic site
was the lung (51%). Because one patient withdrew informed
consent before treatment, 49 patients were evaluated for
efficacy and safety.
Phase I Study
Dose escalation, toxicity and response
The results of phase I are demonstrated in Table 2. At
level 1, one of six patients experienced DLT (grade 3 diar-
rhea). At level 2, two of six patients experienced DLT (two
episodes of neutropenic fever lasting 4 days, one of neu-
tropenia lasting 4 days). At level 3, two of six patients
TABLE 2. Patient Characteristics
Phase I Phase II*
No. of enrolled patients 21 50
No. of assessable patients 21 49
Median age, y (range) 55 (39–65) 52 (35–65)
Gender male/female 12/9 27/23
Performance status
0 6 11
1 15 39
Histology
Adenocarcinoma 19 40
Squamous cell carcinoma 2 6
Large cell carcinoma 0 3
Undifferentiated carcinoma 0 1
Stage
IIIB 7 11
IV 14 39
a Including six patients in the phase I study who were treated with the recommended
doses.
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experienced DLT (two episodes of neutropenia fever lasting
4 days). At level 4, all three patients experienced DLT
including two episodes of grade 4 neutropenia lasting 4 days,
one of grade 3 diarrhea, and one of neutropenic fever lasting
4 days. Neutropenia was prominent at all levels. All patients
experienced grade 4 neutropenia, but the median duration
(range) of500/l neutrophil was 3 days (1–4) at levels 1 to
3. The MTDs and recommended doses for the phase II study
of cisplatin/docetaxel/irinotecan (mg/m2) were thus deter-
mined to be 80/60/60 at level 4 and 60/60/60 at level 3,
respectively.
Phase II Study
Response and survival
A PR was observed in 28 of 49 patients (57.1%; 95%
CI: 43.1%–71.1%) treated as part of the phase II study, 15
had no change (NC) (27.3%), and six (9.1%) in their PD.
Figure 1 shows the overall survival of the 49 patients. At a
median follow-up time of 61.4 months (95% CI: 51.4–71.4
months), seven patients (16.3%) were alive with lung cancer,
and one patient who underwent a left pneumonectomy after
four cycles of triplet chemotherapy was alive without disease.
Three patients had a PS of 0 and five had a PS of 1 at the time
of analysis. The overall survival rates at actual 2, 3, and
estimated 5 years were 33%, 25%, and 18%, respectively.
The median survival time (MST) and the median time to
progression were 17.0 months (95% CI: 14.5–19.4 months)
and 6.2 months (95% CI: 5.4–6.9 months), respectively.
Figure 2 shows the overall survival time of patients
with stage III and IV disease. The MSTs of stage IIIB and IV
disease were 27.6 months (95% CI: 8.6–46.5 months) and
15.2 months (95% CI: 12.3–18.1 months), respectively. The
actual 3-year survival rates for stage IIIB and stage IV disease
were 40% and 21%, respectively. The patients with stage IIIB
lived significantly longer than those with stage IV (p 0.04).
Toxicity
The toxicities observed in 49 patients during the treat-
ment are listed in Tables 4 and 5. The most common toxic-
FIGURE 2. Overall survival for patients with stage IIIB (n 
10) (solid line) and stage IV (n  39) (dotted line) disease in
the phase II study. Censored cases are shown by tics. MST,
median survival time.
TABLE 4. Hematologic Toxicity in the Phase II Study
Grade
0 1 2 3 4 3 and 4 (%)
Leukocytopenia 1 1 4 25 18 43 (89)
Neutropenia 0 2 2 1 44 45 (92)
Anemia 3 13 26 7 0 7 (14)
Thrombocytopenia 23 23 3 0 0 0 (0)
TABLE 5. Nonhematologic Toxicity in the Phase II Study
Grade
0 1 2 3 4 3 and 4 (%)
Nausea/vomiting 5 12 19 12 1 13 (27)
Diarrhea 4 16 12 17 0 17 (35)
Neutropenic fever 27 — — 21 1 22 (45)
Liver 29 11 8 1 0 1 (2)
Constipation 44 1 4 0 0 0
Renal 43 4 2 0 0 0
Peripheral neuropathy 47 2 0 0 0 0
Alopecia 12 11 26 — — 0
Others 47 0 2 0 0 0
TABLE 3. Number of Metastatic Sites and Site of
Metastatic Organs in the Phase II Study
No. of Patients
No. of metastatic sites
1 27
2 7
3 4
Site of metastatic organ
Lung 20
Bone 14
Brain 8
Adrenal 7
Liver 4
Others 3
FIGURE 1. Overall survival for 49 patients with advanced
non-small cell lung cancer in the phase II study. Censored
cases are shown by tics. MST, median survival time; Y-S,
years of survival.
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ities were neutropenia and leukopenia. Grade 3/4 leukopenia
and neutropenia were observed in 43 (89%) and 45 (92%)
patients, respectively. The median neutrophil count of nadir
was 240/l (range, 0–4422/l). The median number of days
to nadir, the median duration of grade 4 neutropenia, and the
median length of the rhG-CSF administration were 9 days
(range, 5–18 days), 3 days (range, 0–7 days) and 6 days
(range, 1–15 days), respectively. rhG-CSF was administered
in 155 (99%) of 157 cycles. Grade 3/4 anemia occurred in
seven (14%) patients, but there was no case of grade 3/4
thrombocytopenia. Grade 3/4 nausea/vomiting, diarrhea, neu-
tropenic fever, and liver dysfunction occurred in 13 (27%), 17
(35%), 22 (45%), and one (2%) patient, respectively. No
treatment-related deaths were observed.
Table 6 summarizes the actual dose delivered of cis-
platin, docetaxel, and irinotecan in the each cycle. Although
55% of the patients completed at least four cycles of chemo-
therapy, 90% dose of each drug was given to the patients
who could receive the fourth cycle of triplet chemotherapy.
Second-Line Treatment
Two patients underwent surgery (a pneumonectomy
and an exploratory thoracotomy) after chemotherapy. Tho-
racic radiotherapy was not given to any patient.
Thirty-one (63%) of 49 patients were treated with
second-line chemotherapy: one regimen eight patients; two
regimens, eight patients; three regimens, nine patients; four or
more regimens, six patients. The same triplet chemotherapy
was repeated in six patients. Other second-line chemotherapy
regimens included other triplet chemotherapy in two, doublet
chemotherapy in 22 (cisplatin  vinorelbine in seven, carbo-
platin  paclitaxel in six, and gemcitabine  vinorelbine in
eight, gemcitabine  paclitaxel in one), and single chemo-
therapy in 42 (vinorelbine in 10, gemcitabine in nine, do-
cetaxel in seven, gemcitabine in seven, and other single
agents in nine). The response rate to the second-line treatment
in the 31 patients was PR in three (9.6%) and NC in 13
(33%). Two patients in cisplatin  docetaxel and one in
carboplatin  paclitaxel achieved a PR with second-line
chemotherapy.
After progression, 18 (37%) patients received gefitinib:
five (28%) attained PR, five (28%) experienced NC, five
(28%) showed PD, and three (16%) could not be evaluated.
Of the 12 patients who survived 3 years, nine (75%)
patients received gefitinib: three attained PR, four experi-
enced NC, one showed PD, and one could not be evaluated.
DISCUSSION
We found the recommended doses of cisplatin/do-
cetaxel/irinotecan for the phase II study involving patients
with advanced NSCLC, aged 65 years or younger, with a
good PS to be 60/60/60 (mg/m2). The DLTs were neutrope-
nia, diarrhea, and neutropenic fever. In the phase II study, the
response rate was 57.1%. The MST and the actual 2-, 3-, and
estimated 5-year survival rates were 17 months and 33%,
25%, and 18%, respectively. The principal toxicities were
neutropenia, diarrhea, and neutropenic fever with no treat-
ment-related death according to admission-based treatment
with adequate supportive care. These findings suggest a
promising efficacy of this combination for advanced NSCLC.
The goal of this study is to pursue the maximum
response toward a complete response, if possible, against
incurable advanced NSCLC using a combination of available
drugs that are covered by the Japanese insurance program. A
triple combination of available drugs was selected based on
the findings of ex vivo and in vivo experiments and clinical
trials. We placed a high priority on a broad antitumor effect
among the two-drug combination and an additive effect rather
than a synergistic one between the two drugs. In addition, we
ruled out the presence of an antagonistic effect between the
two drugs. Finally, we selected a three-drug combination
based on the clinical data from doublet chemotherapy. We
did not abandon the concept of a cure beyond a complete
response; however, we could not reach a complete response.
We obtained a reasonable response rate, more than antici-
pated toxicities, and an unexpected good survival outcome
using this chemotherapy just during the introduction of mo-
lecular targeted agents. A good survival outcome in associa-
tion with a second and a third or more treatment using a
molecular target agent must be clarified to avoid any unseen
bias in future trials.
Although neutropenia and febrile neutropenia were
prominent in this trial, neutropenia was found to be marked in
Japanese compared to the U.S. trial, perhaps because of
ethnic differences.18 The majority of neutropenia and neutro-
penic fever occurred in the first cycle of chemotherapy
because we could not employ prophylactic rhG-CSF at this
cycle. The earlier use of rhG-CSF at the beginning of the first
chemotherapy may have prevented the majority of neutrope-
nia and neutropenic fever.
In Japan, the recommended doses for cisplatin, do-
cetaxel, and irinotecan as single agents are 80, 60, and 200
(mg/m2), respectively. This triplet chemotherapy includes
75% of cisplatin, 100% of docetaxel, and 30% of irinotecan
per one cycle using the full-dose of each drug. Irinotecan
shows a strong interaction with cisplatin in ex vivo experi-
ments and clinical practice. The recommended dose of irino-
tecan per cycle when simultaneously combined with cisplatin
was only 100 mg/m2 and was associated with a marked
response rate; however, grade 3/4 neutropenia and diarrhea
occurred in 70.5% and 25.0% of the patients, respectively,
and one patient died of sepsis.19,20 In the present phase II
TABLE 6. Actual Dose Delivered of Cisplatin, Docetaxel,
and Irinotecan in the Phase II Study
No. of
Cycle
No. of
Patients
No. of Patients
Treated Without
Dose Reduction (%)
Actual Dose (mg/m2)
Delivered of
Cisplatin Docetaxel Irinotecan
1 49 49 (100) 60 60 60
2 44 30 (68) 58 60 57
3 36 20 (56) 59 60 56
4 27 17 (63) 60 60 56
5 6 3 (50) 58 58 53
Kiura et al. Journal of Thoracic Oncology • Volume 2, Number 1, January 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer48
study, grade 3/4 diarrhea developed in 35% of the patients
(Table 5). It thus seems impossible to further escalate the
dose of irinotecan in this setting.
Although this trial included selected patients 65 years
of age or younger and with a good PS, the actual 3-year
survival rate of 25% was higher than expected. However, the
time to progression of triplet chemotherapy was 6 months,
and the MST was 17 months. This indicates the importance of
treatment after initial therapy. Gefitinib failed to prolong the
survival of advanced NSCLC patients,21 but it showed a
dramatic response and a significant survival advantage in a
specific group of patients with advanced NSCLC.22 The
sequential use of gefitinib is widely accepted, and its repro-
ducible response rate is approximately 20% in Japan.23,24
After progression, only 37% of the patients received gefitinib
in the present phase II study because gefitinib was only
approved by the Japanese Ministry of Health, Labor and
Welfare in September 2002. In addition, 27% of the patients
treated with gefitinib achieved a PR. Of the 12 patients who
survived 3 years, nine patients were treated with gefitinib.
As a result, the introduction of gefitinib has therefore pre-
sumably had an impact on survival in this trial.
In general, second-line chemotherapy, such as docetaxel
and pemetrexed, has been demonstrated to prolong survival.25,26
Accordingly, second- and third-line treatments should be taken
into consideration when analyzing the overall survival in the
future trial of advanced NSCLC.
Another possible reason of a favorable survival out-
come is that this trial included relatively more female patients
than male patients and a predominant adenocarcinoma his-
tology was observed. Female gender has been shown to be a
favorable prognostic factor in advanced NSCLC.27 In addi-
tion, Japanese (Asian) female patients with an adenocarci-
noma histology also tend to respond better to gefitinib and
thus are able to survive longer.
The same drugs and schedule against the same popu-
lation showed a different survival outcome between the
Untied States and Japan. In the phase III trial against stage IV
NSCLC comparing cisplatin  docetaxel to vindesine 
cisplatin, the MST and 2-year survival rate for cisplatin 
docetaxel arm were 11.3 months and 24%, respectively.13 In
the phase III trial of ECOG1594 including PS2 and stage IIIB
disease, the MST and 2-year survival rate were 7.4 months
and 11%, respectively.4 A similar phenomenon has been
observed with the treatment of carboplatin and paclitaxel.
The MST and 1-year survival rate for S0003 trial in the
United States versus the Four-Arm Cooperative Study trial in
Japan were 9 months versus 12 months and 37% versus 51%,
respectively.18 The ethnicity was homogeneous in our trial
because the enrolled patients were all Japanese, which might
thus be a possible bias. The genetic molecular backgrounds
between the United States and Japan might be different.28
A phase III trial of cisplatin/docetaxel/irinotecan triplet
chemotherapy versus cisplatin/docetaxel doublet chemother-
apy is presently being carried out in our group.
In conclusion, this triplet chemotherapy was thus found
to be a feasible treatment regimen with severe toxicities, and
it has a highly promising efficacy against advanced NSCLC
when the patients receive admission-based treatment with
adequate supportive care. Further study thus needs to be done
to evaluate the use of prophylactic rhG-CSF in the first cycle
to minimize the toxicity and to develop a new strategy for the
combination treatment with gefitinib in a specific group of
patients with advanced NSCLC.
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